TOP > 外国特許検索 > Bone marrow-directing drug delivery materials and their applications

Bone marrow-directing drug delivery materials and their applications

外国特許コード F110002410
整理番号 100-US
掲載日 2011年2月3日
出願国 アメリカ合衆国
出願番号 91664806
公報番号 20090297608
公報番号 8916197
出願日 平成18年6月5日(2006.6.5)
公報発行日 平成21年12月3日(2009.12.3)
公報発行日 平成26年12月23日(2014.12.23)
国際出願番号 JP2006311676
国際公開番号 WO2006132388
国際出願日 平成18年6月5日(2006.6.5)
国際公開日 平成18年12月14日(2006.12.14)
優先権データ
  • 特願2005-165763 (2005.6.6) JP
  • 2006JP311676 (2006.6.5) WO
発明の名称 (英語) Bone marrow-directing drug delivery materials and their applications
発明の概要(英語) The present invention pertains to a bone marrow-directing drug delivery material that includes at least one fine particle, wherein the fine particle includes an anionic moiety on a surface of the particle.
Also disclosed are uses of the material set forth herein for the prevention, treatment, or diagnosis of a disease of bone, cartilage, bone marrow, or a joint.
Also disclosed are methods of preventing, treating, or diagnosing a disease of bone, cartilage, bone marrow, or a joint in a subject, involving administering to the subject a pharmaceutically effective amount of the material of the present invention.
特許請求の範囲(英語) [claim1]
1. A bone marrow-directing drug delivery material comprising at least one fine particle having a diameter of 20 to 500 nm, wherein the fine particle further comprises: a first amphipathic compound having the following structure:
MOOCR3 -- CO -- HNCH(COOR4)CH2CH2COOR4,
wherein M is a hydrogen atom or a monovalent cation, R3 is -- CH2CH2 -- and R4 is a C10-C22 alkyl group; and
a second amphipathic compound comprising 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[monomethoxy poly(ethylene glycol) (PEG-DSPE).
[claim2]
2. The material of claim 1, wherein the fine particle has a diameter of 100 to 500 nm.
[claim3]
3. The material of claim 1, wherein the particle is further defined as an aggregate of amphipathic molecules that form a vesicle.
[claim4]
4. The material of claim 1, wherein: the first amphipathic compound is present at 1 to 50 mol %, and wherein the second amphipathic compound is present at 0.5 to 4.8 mol %.
[claim5]
5. The material of claim 1, wherein at least one fine particle further comprises a drug bound to the at least one fine particle.
[claim6]
6. A method of preventing, treating, or diagnosing a disease of bone, cartilage, a joint, or bone marrow in a subject, comprising administering to the subject a pharmaceutically effective amount of the material of claim 1.
[claim7]
7. The method of claim 6, wherein the pharmaceutically effective amount of the material is 0.1 to 500 mg of the material per kg of body weight of the subject.
[claim8]
8. The method of claim 6, wherein the subject has a disease of bone marrow.
[claim9]
9. A method of preventing, treating, or diagnosing a joint disease in a subject, comprising administering to the subject a pharmaceutically effective amount of the material of claim 1.
[claim10]
10. The method of claim 9, wherein the pharmaceutically effective amount of the material is 0.1 to 500 mg of the material per kg of body weight of the subject.
[claim11]
11. The method of claim 1, wherein the subject is a human.
[claim12]
12. A kit comprising a predetermined amount of the material of claim 1 and a sealed container.
  • 発明者/出願人(英語)
  • SOU KEITARO
  • TAKEOKA SHINJI
  • TSUCHIDA EISHUN
  • GOINS BETH A
  • PHILLIPS WILLIAM T
  • THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
  • WASEDA UNIVERSITY
国際特許分類(IPC)
米国特許分類/主・副
  • 424/489
  • 424/400
  • 977/906
技術導入、技術提携、実用化開発(受託研究・共同研究等)のご相談を承っております。お気軽にご連絡ください。

PAGE TOP

close
close
close
close
close
close